Literature DB >> 2831402

Identification and expression of a human cytomegalovirus glycoprotein with homology to the Epstein-Barr virus BXLF2 product, varicella-zoster virus gpIII, and herpes simplex virus type 1 glycoprotein H.

M P Cranage1, G L Smith, S E Bell, H Hart, C Brown, A T Bankier, P Tomlinson, B G Barrell, T C Minson.   

Abstract

An open reading frame with the characteristics of a glycoprotein-coding sequence was identified by nucleotide sequencing of human cytomegalovirus (HCMV) genomic DNA. The predicted amino acid sequence was homologous with glycoprotein H of herpes simplex virus type 1 and the homologous protein of Epstein-Barr virus (BXLF2 gene product) and varicella-zoster virus (gpIII). Recombinant vaccinia viruses that expressed this gene were constructed. A glycoprotein of approximately 86 kilodaltons was immunoprecipitated from cells infected with the recombinant viruses and from HCMV-infected cells with a monoclonal antibody that efficiently neutralized HCMV infectivity. In HCMV-infected MRC5 cells, this glycoprotein was present on nuclear and cytoplasmic membranes, but in recombinant vaccinia virus-infected cells it accumulated predominantly on the nuclear membrane.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2831402      PMCID: PMC253155          DOI: 10.1128/JVI.62.4.1416-1422.1988

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  40 in total

1.  DNA sequence and expression of the B95-8 Epstein-Barr virus genome.

Authors:  R Baer; A T Bankier; M D Biggin; P L Deininger; P J Farrell; T J Gibson; G Hatfull; G S Hudson; S C Satchwell; C Séguin
Journal:  Nature       Date:  1984 Jul 19-25       Impact factor: 49.962

2.  Characterisation and physical mapping of an HSV-1 glycoprotein of approximately 115 X 10(3) molecular weight.

Authors:  E A Buckmaster; U Gompels; A Minson
Journal:  Virology       Date:  1984-12       Impact factor: 3.616

3.  Graphic methods to determine the function of nucleic acid sequences.

Authors:  R Staden
Journal:  Nucleic Acids Res       Date:  1984-01-11       Impact factor: 16.971

4.  Congenital and perinatal cytomegalovirus infections.

Authors:  S Stagno; R F Pass; M E Dworsky; C A Alford
Journal:  Semin Perinatol       Date:  1983-01       Impact factor: 3.300

5.  Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen.

Authors:  G L Smith; M Mackett; B Moss
Journal:  Nature       Date:  1983-04-07       Impact factor: 49.962

6.  General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes.

Authors:  M Mackett; G L Smith; B Moss
Journal:  J Virol       Date:  1984-03       Impact factor: 5.103

7.  Protection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein gene.

Authors:  T J Wiktor; R I Macfarlan; K J Reagan; B Dietzschold; P J Curtis; W H Wunner; M P Kieny; R Lathe; J P Lecocq; M Mackett
Journal:  Proc Natl Acad Sci U S A       Date:  1984-11       Impact factor: 11.205

8.  Murine monoclonal antibody to a single protein neutralizes the infectivity of human cytomegalovirus.

Authors:  L E Rasmussen; R M Nelson; D C Kelsall; T C Merigan
Journal:  Proc Natl Acad Sci U S A       Date:  1984-02       Impact factor: 11.205

9.  Neutralizing antibodies detect a disulfide-linked glycoprotein complex within the envelope of human cytomegalovirus.

Authors:  W J Britt
Journal:  Virology       Date:  1984-06       Impact factor: 3.616

10.  Polymorphism of human cytomegalovirus glycoproteins characterized by monoclonal antibodies.

Authors:  L Pereira; M Hoffman; M Tatsuno; D Dondero
Journal:  Virology       Date:  1984-11       Impact factor: 3.616

View more
  62 in total

1.  Distinct glycoprotein O complexes arise in a post-Golgi compartment of cytomegalovirus-infected cells.

Authors:  Regan N Theiler; Teresa Compton
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

2.  Functional analysis of the true late human cytomegalovirus pp28 upstream promoter: cis-acting elements and viral trans-acting proteins necessary for promoter activation.

Authors:  A S Depto; R M Stenberg
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

3.  Glycoprotein H of pseudorabies virus is essential for entry and cell-to-cell spread of the virus.

Authors:  B Peeters; N de Wind; R Broer; A Gielkens; R Moormann
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

Review 4.  Epstein-Barr virus tissue tropism: a major determinant of immunopathogenesis.

Authors:  L Hutt-Fletcher
Journal:  Springer Semin Immunopathol       Date:  1991

5.  Expression of a human cytomegalovirus glycoprotein multigene family.

Authors:  D R Gretch; J F Bale; R C Gehrz; M F Stinski
Journal:  Virus Genes       Date:  1991-07       Impact factor: 2.332

6.  Cloning and characterization of major antigenic determinants of human cytomegalovirus Ad169 seen by the human immune system.

Authors:  W Lindenmaier; A Necker; S Krause; R Bonewald; J Collins
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

7.  Depletion of glycoprotein gp85 from virosomes made with Epstein-Barr virus proteins abolishes their ability to fuse with virus receptor-bearing cells.

Authors:  R S Haddad; L M Hutt-Fletcher
Journal:  J Virol       Date:  1989-12       Impact factor: 5.103

8.  Postoligomerization folding of human cytomegalovirus glycoprotein B: identification of folding intermediates and importance of disulfide bonding.

Authors:  M A Billstrom; W J Britt
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

9.  Identification and characterization of a novel structural glycoprotein in pseudorabies virus, gL.

Authors:  B G Klupp; J Baumeister; A Karger; N Visser; T C Mettenleiter
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

10.  Intracellular processing of human herpesvirus 6 glycoproteins Q1 and Q2 into tetrameric complexes expressed on the viral envelope.

Authors:  Pilailuk Akkapaiboon; Yasuko Mori; Tomohiko Sadaoka; Sayoko Yonemoto; Koichi Yamanishi
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.